Correlation between RICTOR overexpression and amplification in advanced solid tumors

被引:9
作者
Bang, Heejin [1 ,2 ]
Ahn, Soomin [2 ,3 ]
Kim, Eun Ji [2 ]
Kim, Seung Tae [4 ]
Park, Ha Young [5 ]
Lee, Jeeyun [4 ]
Kim, Kyoung-Mee [2 ,6 ]
机构
[1] Hallym Univ, Kangnam Sacred Heart Hosp, Coll Med, Dept Pathol, Seoul, South Korea
[2] Samsung Med Ctr, Ctr Compan Diagnost, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Seongnam, Gyeonggi, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Seoul, South Korea
[5] Inje Univ, Busan Paik Hosp, Coll Med, Dept Pathol, Busan, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 135710, South Korea
基金
新加坡国家研究基金会;
关键词
RICTOR; Immunohistochemistry; Fluorescence in situ hybridization; Target; PREDICTS GENE AMPLIFICATION; COLORECTAL-CANCER; LUNG-CANCER; MTOR; EXPRESSION; IMMUNOHISTOCHEMISTRY; PROGRESSION; DEFINES; PROTEIN; PATHWAY;
D O I
10.1016/j.prp.2019.152734
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Rapamycin-insensitive companion of mTOR (RICTOR) is a key component of mammalian target of rapamycin (mTOR) complex 2 (mTORC2), and promotes cellular proliferation and survival through the activation of downstream AGC kinase family members. The amplification of RICTOR has been proposed as a therapeutically relevant genomic alteration. However, other than next-generation sequencing, precise diagnostic methods to detect RICTOR amplification in advanced solid cancers have not been fully explored. We performed immunohistochemistry (IHC) analysis on solid tumor tissues from 435 cancer patients. Overexpression of RICTOR was found in 213 cases (49.0 %: 1+, 29.4 %; 2+, 15.2 %; 3+, 4.4 %) consisting of 111 colorectal cancers, 42 gastric cancers, 16 renal cell carcinomas, 8 soft tissue sarcomas, 6 hepatocellular carcinomas, 6 cholangiocarcinomas, 4 lung cancers, and 37 other tumors. RICTOR overexpression was heterogeneous (stained < 50 0 /0 of the tumor volume) in 32.4 % (12/37) of IHC-positive cases. We performed fluorescence in situ hybridization (FISH) in 37 RICTOR-overexpressed IHC-positive cases (1+, 12; 2+, 11; 3+, 14) and 13 IHC-negative solid tumors. FISH enabled us to detect RICTOR amplification in 7/12 (58.3 %) IHC 1+, 10/11 (90.9 %) IHC 2+, and 11/14 (78.6 %) IHC 3+ cases. In total, there was amplification in 75.7 % (n = 28) of the RICTOR-overexpressed cases, according to FISH. There was RICTOR amplification in only 7.7 % of the RICTOR IHC-negative cases. RICTOR amplification was significantly more common in IHC-positive cases than in IHC-negative cases (p < 0.0001). The IHC results correlated well with those of FISH (r = 0.60). RICTOR overexpression is more common in solid tumors than previously reported in cases detected by next-generation sequencing. This discrepancy may be caused by intratumoral heterogeneity. In conclusion, heterogeneous RICTOR overexpression is common in solid tumors and RICTOR IHC can be used as a screening tool to detect RICTOR amplification.
引用
收藏
页数:5
相关论文
共 22 条
[1]   FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival [J].
Ahn, Soomin ;
Lee, Jeeyun ;
Hong, Mineui ;
Kim, Seung Tae ;
Park, Se Hoon ;
Choi, Min Gew ;
Lee, Jun-Ho ;
Sohn, Tae Sung ;
Bae, Jae Moon ;
Kim, Sung ;
Jung, Sin-Ho ;
Kang, Won Ki ;
Kim, Kyoung-Mee .
MODERN PATHOLOGY, 2016, 29 (09) :1095-1103
[2]   A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer [J].
Ahn, Soomin ;
Hong, Mineui ;
Van Vrancken, Michael ;
Lyou, You Jeong ;
Kim, Seung Tae ;
Park, Se Hoon ;
Kang, Won Ki ;
Park, Young Suk ;
Jung, Sin-Ho ;
Woo, Minah ;
Lee, Jeeyun ;
Kim, Kyoung-Mee .
MOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (04) :375-383
[3]   Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer [J].
Bian, Yuhai ;
Wang, Zhengshi ;
Xu, Jia ;
Zhao, Wenyi ;
Cao, Hui ;
Zhang, Zhigang .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (02) :534-540
[4]   RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors [J].
Cheng, Haiying ;
Zou, Yiyu ;
Ross, Jeffrey S. ;
Wang, Kai ;
Liu, Xuewen ;
Halmos, Balazs ;
Ali, Siraj M. ;
Liu, Huijie ;
Verma, Amit ;
Montagna, Cristina ;
Chachoua, Abraham ;
Goel, Sanjay ;
Schwartz, Edward L. ;
Zhu, Changcheng ;
Shan, Jidong ;
Yu, Yiting ;
Gritsman, Kira ;
Yelensky, Roman ;
Lipson, Doron ;
Otto, Geoff ;
Hawryluk, Matthew ;
Stephens, Philip J. ;
Miller, Vincent A. ;
Piperdi, Bilal ;
Perez-Soler, Roman .
CANCER DISCOVERY, 2015, 5 (12) :1262-1270
[5]   Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas [J].
Cho, Eun Yoon ;
Srivastava, Amitabh ;
Park, Kyeongmee ;
Kim, Jiyun ;
Lee, Min Hyeong ;
Do, Ingu ;
Lee, Jeeyun ;
Kim, Kyoung-Mee ;
Sohn, Tae Sung ;
Kang, Won Ki ;
Kim, Sung .
PATHOLOGY, 2012, 44 (03) :216-220
[6]   Defining the role of mTOR in cancer [J].
Guertin, David A. ;
Sabatini, David M. .
CANCER CELL, 2007, 12 (01) :9-22
[7]   mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways [J].
Gulhati, Pat ;
Bowen, Kanika A. ;
Liu, Jianyu ;
Stevens, Payton D. ;
Rychahou, Piotr G. ;
Chen, Min ;
Lee, Eun Y. ;
Weiss, Heidi L. ;
O'Connor, Kathleen L. ;
Gao, Tianyan ;
Evers, B. Mark .
CANCER RESEARCH, 2011, 71 (09) :3246-3256
[8]   MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas [J].
Ha, Sang Y. ;
Lee, Jeeyun ;
Kang, So Y. ;
Do, In-Gu ;
Ahn, Soomin ;
Park, Joon O. ;
Kang, Won K. ;
Choi, Min-Gew ;
Sohn, Tae S. ;
Bae, Jae M. ;
Kim, Sung ;
Kim, Minji ;
Kim, Seonwoo ;
Park, Cheol K. ;
Ou, Sai-Hong Ignatius ;
Kim, Kyoung-Mee .
MODERN PATHOLOGY, 2013, 26 (12) :1632-1641
[9]  
Jung KS, 2017, MOL CLIN ONCOL, V7, P27, DOI 10.3892/mco.2017.1272
[10]   Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma [J].
Kaibori, Masaki ;
Shikata, Nobuaki ;
Sakaguchi, Tatsuma ;
Ishizaki, Morihiko ;
Matsui, Kosuke ;
Iida, Hiroya ;
Tanaka, Yoshito ;
Miki, Hirokazu ;
Nakatake, Richi ;
Okumura, Tadayoshi ;
Tokuhara, Katsuji ;
Inoue, Kentaro ;
Wada, Jouji ;
Oda, Michio ;
Nishizawa, Mikio ;
Kon, Masanori .
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (04) :919-928